Radiation dosimetry, safety and pharmacokinetics of [11C]telmisartan as well as optimization of PET imaging in healthy volunteers

Radiation dosimetry, safety and pharmacokinetics of [11C]telmisartan as well as optimization of PET imaging in healthy volunteers - Pharmacokinetics of [11C]telmisartan in healthy volunteers (TEL-0)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002446

Enrollment

Registered

2009-09-07

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

To inject [11C]telmisartan intravenously for PET imaging.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Normal subjects with body weight >= 50kg and <85kg, and body mass index >= 17.6 and <26.4.

Exclusion criteria

Exclusion criteria: 1. Renal artery stenosis, bilaterally or unilaterally after nephrectomy 2. Hyperkalemia 3. Liver or renal dysfunction 4. Cerebrovascular disorders 5. Hypotension 6. Severe bradycardia, or WPW or LGL syndrome by ECG 7. Medication or dietary supplement including St. John's wort within 7 days prior to PET study

Design outcomes

Primary

Measure	Time frame
Safety, radiation dosimetry, plasma concentration time course and whole-body pharmacokinetics of [11C]telmisartan.	—

Countries

Japan

Contacts

Public ContactMichio Senda

Foundation for Biomedical Research and Innovation Division of Molecular Imaging, Institute of Biomedical Research and Innovation

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026